Cargando…

Practical consideration for successful sequential tumor biopsies in first-in-human trials

In first-in-human (FIH) trials, sequential tumor biopsies, i.e., two consecutive tumor biopsies, the first performed at baseline (pretreatment) and the second during the early treatment period (on-treatment), provide proof of concept in investigational new drugs. We evaluated the success of sequenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koyama, Takafumi, Shimizu, Toshio, Sato, Jun, Katsuya, Yuki, Iwasa, Satoru, Kondo, Shunsuke, Yoshida, Tatsuya, Sudo, Kazuki, Nishino, Makoto, Takiguchi, Yuichi, Yonemori, Kan, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288361/ https://www.ncbi.nlm.nih.gov/pubmed/35404018 http://dx.doi.org/10.1007/s10637-022-01236-4

Ejemplares similares

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
por: Kuboki, Yasutoshi, et al.
Publicado: (2022)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
por: Kondo, Shunsuke, et al.
Publicado: (2022)

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)

Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
por: Shimizu, Toshio, et al.
Publicado: (2022)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
por: Mizuno, Takaaki, et al.
Publicado: (2022)

Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) study
por: Nishino, Makoto, et al.
Publicado: (2023)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice
por: Ida, Hanae, et al.
Publicado: (2022)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2017)

A Mathematical Model of the Olfactory Bulb for the Selective Adaptation Mechanism in the Rodent Olfactory System
por: Soh, Zu, et al.
Publicado: (2016)

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
por: Fujiwara, Yutaka, et al.
Publicado: (2021)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
por: Kitadai, Rui, et al.
Publicado: (2021)

PEDT-12 NATIONWIDE LANDSCAPE OF GENOMIC ANALYSIS OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS
por: Watanabe, Yuko, et al.
Publicado: (2022)

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system
por: Shimoi, Tatsunori, et al.
Publicado: (2018)

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
por: Sunami, Kuniko, et al.
Publicado: (2019)

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial
por: Okuma, Hitomi S., et al.
Publicado: (2020)

Spatial and temporal responses of metastatic renal cell carcinoma lesions to sequential treatments over a 10‐year period
por: Kobayashi, Hirohito, et al.
Publicado: (2018)

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
por: Doi, Toshihiko, et al.
Publicado: (2021)

Techniques of Skin Biopsy and Practical Considerations
por: Nischal, Urmila, et al.
Publicado: (2008)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2021)

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
por: Saito, Ayumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pao1hok84op2792vai47r2d7ao